Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Heavy Cash Burn ⢠Equity Dilution CLDX is well-capitalized with substantial liquidity and minimal debt, but severe losses, cash burn, negligible revenue, and equity dilution make it a high-risk, financing-dependent investment.
Price Behavior
Key Price Behavior Insights: ⢠Downward bias ⢠Fragile rebound ⢠Weak momentum Support Level: $36.90â$38.10 Resistance Level: $39.18â$39.68 CLDX remains technically weak over the last month, with downside risk below $36.90 and a more constructive outlook only if it reclaims $39.70â$40.40.
Sentiment & News
Key News Insights: ⢠Shareholder Investigation ⢠Investor Outreach ⢠Institutional Buying Celldex faces shareholder scrutiny while boosting investor engagement and attracting new institutional ownership.
AI Summary
Celldex is now a high-risk clinical execution bet: despite ample liquidity, the barzolvolimab Phase 2 failure raises the proof threshold for its core asset, so investors should wait for convincing follow-on efficacy data and monitor burn-driven dilution rather than rely on cash as downside protection.
Description
Celldex Therapeutics is a biopharmaceutical company developing monoclonal and bispecific antibody therapies for inflammatory conditions and various cancers. Its clinical pipeline includes programs directed at KIT, CD40 and a bispecific combining PD-L1 blockade with CD27 costimulation, among other antibody candidates. The company maintains research and licensing relationships with academic institutions and Amgen, and is headquartered in Hampton, New Jersey, having been incorporated in 1983.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 26 | Mar 5 | CLDX | Celldex Therapeutics, Inc. | Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade. | Closed | -4.2% |